Summary
Gilead Sciences, Inc. (GILD) announced on June 23, 2010, through a Form 8-K filing, its entry into a definitive Agreement and Plan of Merger to acquire CGI Pharmaceuticals, Inc. (CGI). The transaction involves Gilead's wholly-owned subsidiary, Cougar Merger Sub, Inc., merging with CGI, making CGI a wholly-owned subsidiary of Gilead upon completion. This strategic acquisition is valued at up to $120 million in cash. A portion of this consideration is contingent on the fulfillment of specific post-closing milestones, and another portion will be held in escrow to cover potential indemnity claims. The filing indicates that the merger is subject to customary closing conditions and regulatory approvals, though it is not expected to require Hart-Scott-Rodino antitrust review. This move signifies Gilead's ongoing efforts to expand its pipeline and market presence through targeted acquisitions.
Key Highlights
- 1Gilead Sciences, Inc. entered into a Merger Agreement to acquire CGI Pharmaceuticals, Inc. for up to $120 million in cash.
- 2The acquisition is structured as a merger where CGI will become a wholly-owned subsidiary of Gilead.
- 3A portion of the acquisition price is contingent on achieving specific post-closing milestones.
- 4Part of the payment will be placed in escrow to cover potential indemnity obligations.
- 5The transaction is subject to standard closing conditions and regulatory approvals.
- 6The merger is not subject to review under the Hart-Scott-Rodino Antitrust Improvements Act.
- 7The announcement was made via a joint press release on June 25, 2010, filed as an exhibit to the 8-K.